Global Orphan Drug Market: Industry Analysis and forecast 2027: Drug Type, Sale, Therapy Class, Application, and Region.

Global Orphan Drug Market size was valued US$ XX Mn in 2019 and the total revenue is expected to grow at 4.83 % through 2020 to 2027, reaching US$ XX Mn. The report has covered Country market trends with a competitive landscape. To know about the Research Methodology :- Request Free Sample Report

Global Orphan Drug Market Overview:

The number of patients suffering from uncommon disorders is less, & due to these pharmaceutical productions do not entertain the production of drugs for the same. Due to the less acceptance rate of these unusual drugs, they are named as orphan drugs. Orphan drugs are those that establishments are not supposed to get much benefit from & instead direct their exertions at drugs which will bring in profit. To deliver proper treatment for rare disease & to encourage pharmaceutical & biotechnology firms to invest in treatment for unusual diseases, governments have shaped different legal & financial incentives. The factors like the increasing occurrence of rare diseases & rising investment in R&D are anticipated to increase the development of the market. Conclusively, the growing growth of new technologies for an orphan drug is likely to offer huge opportunities for market development during the forecast period. A rare disease, also mentioned to as an orphan disease, is any disease which affects a minor percentage of the populace. Most of the infrequent diseases are genetic & are present through a person's whole life, even if signs do not directly appear. Across the world, there is a growing occurrence of rare disease. According to the survey carried out in the year 2018, 6,084 rare diseases were recounted in the United States. Some circumstances can affect only a handful of individuals, while others may affect hundreds or thousands, like cystic fibrosis, which affects about 30,000 people in the US. All together infrequent disease patients include about 6 percent to 8 percent of the populace. According to MMR study, the factors responsible for the increasing occurrence of the rare disease is owing to growing paternal & maternal ages & augmented use of fertility therapies. There are different reasons of rare diseases. The majority of them are genetic, directly produced by changes in genes. Orphan drugs market has been newly accepted as a promising therapeutic market as the diseases that are covered under the market are serious diseases. The FDA & EMA have selected a drug as an orphan drug for which the cases in the United States are less than 0.2 Mn & not more than 5 in 10,000 persons through the EU. Earlier the orphan drug sector was ignored by the big pharmaceutical firms as emerging & marketing of these drugs was measured not so profitable. Majority of the R&D activities associated with orphan drugs were done by small size pharmaceutical companies & less than 25 percent of the orphan drugs were being R&D by the large companies. The entry of mid & large size pharmaceutical establishments assisted in speeding up the medical research activities associated with orphan drugs. The number of medical trials improved extremely in the past few years to more than 500 for orphan drugs as associated with a few hundred trials at the beginning of the 21st century. Now, more than four orphan designated drugs are commercially existing in the marketed & close to thousand drugs are experiencing clinical trials. The number of medical trials covering the rare diseases has been observed to increase in recent years with major participation of companies like Roche, Celgene, AbbVie, Johnson & Johnson, and Bayer. The numerous main key players & the increasing demand for the orphan drugs clearly shows the growth that the market will experience during the forecast period. North America accounted for the major market share of 41.98% in the year 2018. The United States is projected to dominate the total orphan drugs market during the review period. The market development in this region is mainly owing to the growing occurrence of rare disorders. The European market for orphan drugs is anticipated to be the second largest during the forecast period. The growing number of pharmaceutical establishments exporting their products outside or within Europe is anticipated to pay to market development. Most of the European firms are involved in R&D of orphan drugs according to the patient’s need. The orphan drugs market in Europe is anticipated to produce numerous folds in the coming years owing to numerous favorable factors like the introduction of advanced technologies, reasonable pricing, unmet medical necessities, & strong clinical pipeline. Asia Pacific is expected to be the fastest growing market due to the developing healthcare infrastructure. Owing to growing population, Asia has enormous long-term potential for orphan drug medicines & treatments. Due to the growing occurrence of new diseases like endocrinology, cardiovascular & lymphatic systems, as well as respiratory disorders, the market development for orphan drugs is witnessed in this region during the forecast period.

Global Orphan Drug Market Competitive Landscape:

The objective of the report is to present a comprehensive analysis of the Global Orphan Drug Market including all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all the aspects of the industry with a dedicated study of key players that includes market leaders, followers, and new entrants. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors of the market have been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give a clear futuristic view of the industry to the decision-makers. The report also helps in understanding Global Orphan Drug Market dynamics, structure by analyzing the market segments and project the Global Orphan Drug Market size. Clear representation of competitive analysis of key players by Type, price, financial position, Raw material portfolio, growth strategies, and regional presence in the Global Orphan Drug Market make the report investor’s guide.

Scope of Global Orphan Drug Market: Inquire before buying

Global Orphan Drug Market, By Drug Type

• Biologics • Non-Biologics

Global Orphan Drug Market, By Sale

• Generics • Prescribed

Global Orphan Drug Market, By Therapy Class

• Oncology • Blood • Central Nervous Systems • Endocrine • Cardiovascular • Respiratory

Global Orphan Drug Market, by Region

• North America • Europe • Asia-Pacific • MEA & Africa • Latin America

Global Orphan Drug Market Key Players

• AOP Orphan • Agenus • Alexion • Bristol Myers Squibb • Biogen Idec • Celgene • Eli Lilly • Genethon • Genzyme Corporation • Glaxosmithkline • Merck • Novartis Pharmaceuticals • Orphan Europe • Pfizer • Prosensa • Rare Disease Therapeutics • Roche • Sanofi • Shire • Teva Pharmaceutical
Global Orphan Drug Market 1. Preface 1.1. Report Scope and Market Segmentation 1.2. Research Highlights 1.3. Research Objectives 2. Assumptions and Research Methodology 2.1. Report Assumptions 2.2. Abbreviations 2.3. Research Methodology 2.3.1. Secondary Research 2.3.1.1. Secondary data 2.3.1.2. Secondary Sources 2.3.2. Primary Research 2.3.2.1. Data from Primary Sources 2.3.2.2. Breakdown of Primary Sources 3. Executive Summary: Global Orphan Drug Market Size, by Market Value (US$ Mn) 4. Market Overview 4.1. Introduction 4.2. Market Indicator 4.2.1. Drivers 4.2.2. Restraints 4.2.3. Opportunities 4.2.4. Challenges 4.3. Porter’s Analysis 4.4. Value Chain Analysis 4.5. Market Risk Analysis 4.6. SWOT Analysis 4.7. Industry Trends and Emerging Technologies 5. Supply Side and Demand Side Indicators 6. Global Orphan Drug Market Analysis and Forecast 7. Global Orphan Drug Market Analysis and Forecast, by Drug Type 7.1. Introduction and Definition 7.2. Key Findings 7.3. Global Orphan Drug Market Value Share Analysis, by Drug Type 7.4. Global Orphan Drug Market Size (US$ Mn) Forecast, by Drug Type 7.5. Global Orphan Drug Market Analysis, by Drug Type 7.6. Global Orphan Drug Market Attractiveness Analysis, by Drug Type 8. Global Orphan Drug Market Analysis and Forecast, by Sale 8.1. Introduction and Definition 8.2. Key Findings 8.3. Global Orphan Drug Market Value Share Analysis, by Sale 8.4. Global Orphan Drug Market Size (US$ Mn) Forecast, by Sale 8.5. Global Orphan Drug Market Analysis, by Sale 8.6. Global Orphan Drug Market Attractiveness Analysis, by Sale 9. Global Orphan Drug Market Analysis and Forecast, by Therapy Class 9.1. Introduction and Definition 9.2. Key Findings 9.3. Global Orphan Drug Market Value Share Analysis, by Therapy Class 9.4. Global Orphan Drug Market Size (US$ Mn) Forecast, by Therapy Class 9.5. Global Orphan Drug Market Analysis, by Therapy Class 9.6. Global Orphan Drug Market Attractiveness Analysis, by Therapy Class 10. Global Orphan Drug Market Analysis and Forecast, by Region 10.1. Introduction and Definition 10.2. Key Findings 10.3. Global Orphan Drug Market Value Share Analysis, by Region 10.4. Global Orphan Drug Market Size (US$ Mn) Forecast, by Region 10.5. Global Orphan Drug Market Analysis, by Region 11. Global Orphan Drug Market Analysis 11.1. Key Findings 11.2. Global Orphan Drug Market Overview 11.3. Global Orphan Drug Market Forecast, by Drug Type 11.3.1. Biologics 11.3.2. Non-Biologics 11.4. Global Orphan Drug Market Forecast, by Sale 11.4.1. Generics 11.4.2. Prescribed 11.5. Global Orphan Drug Market Forecast, by Therapy Class 11.5.1. Oncology 11.5.2. Blood 11.5.3. Central Nervous Systems 11.5.4. Endocrine 11.5.5. Cardiovascular 11.5.6. Respiratory 11.6. Global Orphan Drug Market Forecast, by Region 11.6.1. North America 11.6.2. Europe 11.6.3. Asia-Pacific 11.6.4. MEA & Africa 11.6.5. Latin America 11.7. PEST Analysis 11.8. Key Trends 11.9. Key Developments 12. North America Orphan Drug Market Analysis 12.1. Key Findings 12.2. North America Orphan Drug Market Forecast, by Drug Type 12.2.1. Biologics 12.2.2. Non-Biologics 12.3. North America Orphan Drug Market Forecast, by Sale 12.3.1. Generics 12.3.2. Prescribed 12.4. North America Orphan Drug Market Forecast, by Therapy Class 12.4.1. Oncology 12.4.2. Blood 12.4.3. Central Nervous Systems 12.4.4. Endocrine 12.4.5. Cardiovascular 12.4.6. Respiratory 12.5. North America Orphan Drug Market Forecast, by Country 12.5.1. US 12.5.2. Canada 12.6. US Orphan Drug Market Forecast, by Drug Type 12.6.1. Biologics 12.6.2. Non-Biologics 12.7. US Orphan Drug Market Forecast, by Sale 12.7.1. Generics 12.7.2. Prescribed 12.8. US Orphan Drug Market Forecast, by Therapy Class 12.8.1. Oncology 12.8.2. Blood 12.8.3. Central Nervous Systems 12.8.4. Endocrine 12.8.5. Cardiovascular 12.8.6. Respiratory 12.9. Canada Orphan Drug Market Forecast, by Drug Type 12.9.1. Biologics 12.9.2. Non-Biologics 12.10. Canada Orphan Drug Market Forecast, by Sale 12.10.1. Generics 12.10.2. Prescribed 12.11. Canada Orphan Drug Market Forecast, by Therapy Class 12.11.1. Oncology 12.11.2. Blood 12.11.3. Central Nervous Systems 12.11.4. Endocrine 12.11.5. Cardiovascular 12.11.6. Respiratory 12.12. PEST Analysis 12.13. Key Trends 12.14. Key Developments 13. Europe Orphan Drug Market Analysis 13.1. Key Findings 13.2. Europe Orphan Drug Market Overview 13.3. Europe Orphan Drug Market Forecast, by Drug Type 13.3.1. Biologics 13.3.2. Non-Biologics 13.4. Europe Orphan Drug Market Forecast, by Sale 13.4.1. Generics 13.4.2. Prescribed 13.5. Europe Orphan Drug Market Forecast, by Therapy Class 13.5.1. Oncology 13.5.2. Blood 13.5.3. Central Nervous Systems 13.5.4. Endocrine 13.5.5. Cardiovascular 13.5.6. Respiratory 13.6. Europe Orphan Drug Market Forecast, by Country 13.6.1. UK 13.6.2. France 13.6.3. Germany 13.6.4. Russia 13.6.5. Italy 13.6.6. Rest of Europe 13.7. UK Orphan Drug Market Forecast, by Drug Type 13.7.1. Biologics 13.7.2. Non-Biologics 13.8. UK Orphan Drug Market Forecast, by Sale 13.8.1. Generics 13.8.2. Prescribed 13.9. UK Orphan Drug Market Forecast, by Therapy Class 13.9.1. Oncology 13.9.2. Blood 13.9.3. Central Nervous Systems 13.9.4. Endocrine 13.9.5. Cardiovascular 13.9.6. Respiratory 13.10. France Orphan Drug Market Forecast, by Drug Type 13.10.1. Biologics 13.10.2. Non-Biologics 13.11. France Orphan Drug Market Forecast, by Sale 13.11.1. Generics 13.11.2. Prescribed 13.12. France Orphan Drug Market Forecast, by Therapy Class 13.12.1. Oncology 13.12.2. Blood 13.12.3. Central Nervous Systems 13.12.4. Endocrine 13.12.5. Cardiovascular 13.12.6. Respiratory 13.13. Germany Orphan Drug Market Forecast, by Drug Type 13.13.1. Biologics 13.13.2. Non-Biologics 13.14. Germany Orphan Drug Market Forecast, by Sale 13.14.1. Generics 13.14.2. Prescribed 13.15. Germany Orphan Drug Market Forecast, by Therapy Class 13.15.1. Oncology 13.15.2. Blood 13.15.3. Central Nervous Systems 13.15.4. Endocrine 13.15.5. Cardiovascular 13.15.6. Respiratory 13.16. Russia Orphan Drug Market Forecast, by Drug Type 13.16.1. Biologics 13.16.2. Non-Biologics 13.17. Russia Orphan Drug Market Forecast, by Sale 13.17.1. Generics 13.17.2. Prescribed 13.18. Russia Orphan Drug Market Forecast, by Therapy Class 13.18.1. Oncology 13.18.2. Blood 13.18.3. Central Nervous Systems 13.18.4. Endocrine 13.18.5. Cardiovascular 13.18.6. Respiratory 13.19. Italy Orphan Drug Market Forecast, by Drug Type 13.19.1. Biologics 13.19.2. Non-Biologics 13.20. Italy Orphan Drug Market Forecast, by Sale 13.20.1. Generics 13.20.2. Prescribed 13.21. Italy Orphan Drug Market Forecast, by Therapy Class 13.21.1. Oncology 13.21.2. Blood 13.21.3. Central Nervous Systems 13.21.4. Endocrine 13.21.5. Cardiovascular 13.21.6. Respiratory 13.22. Rest of Europe Orphan Drug Market Forecast, by Drug Type 13.22.1. Biologics 13.22.2. Non-Biologics 13.23. Rest of Europe Orphan Drug Market Forecast, by Sale 13.23.1. Generics 13.23.2. Prescribed 13.24. Rest of Europe Orphan Drug Market Forecast, by Therapy Class 13.24.1. Oncology 13.24.2. Blood 13.24.3. Central Nervous Systems 13.24.4. Endocrine 13.24.5. Cardiovascular 13.24.6. Respiratory 13.25. PEST Analysis 13.26. Key Trends 13.27. Key Developments 14. Asia Pacific Orphan Drug Market Analysis 14.1. Key Findings 14.2. Asia Pacific Orphan Drug Market Overview 14.3. Asia Pacific Orphan Drug Market Forecast, by Drug Type 14.3.1. Biologics 14.3.2. Non-Biologics 14.4. Asia Pacific Orphan Drug Market Forecast, by Sale 14.4.1. Generics 14.4.2. Prescribed 14.5. Asia Pacific Orphan Drug Market Forecast, by Therapy Class 14.5.1. Oncology 14.5.2. Blood 14.5.3. Central Nervous Systems 14.5.4. Endocrine 14.5.5. Cardiovascular 14.5.6. Respiratory 14.6. Asia Pacific Orphan Drug Market Forecast, by Country 14.6.1. China 14.6.2. India 14.6.3. Japan 14.6.4. Malaysia 14.6.5. Indonesia 14.6.6. Rest of Asia-Pacific 14.7. China Orphan Drug Market Forecast, by Drug Type 14.7.1. Biologics 14.7.2. Non-Biologics 14.8. China Orphan Drug Market Forecast, by Sale 14.8.1. Generics 14.8.2. Prescribed 14.9. China Orphan Drug Market Forecast, by Therapy Class 14.9.1. Oncology 14.9.2. Blood 14.9.3. Central Nervous Systems 14.9.4. Endocrine 14.9.5. Cardiovascular 14.9.6. Respiratory 14.10. India Orphan Drug Market Forecast, by Drug Type 14.10.1. Biologics 14.10.2. Non-Biologics 14.11. India Orphan Drug Market Forecast, by Sale 14.11.1. Generics 14.11.2. Prescribed 14.12. India Orphan Drug Market Forecast, by Therapy Class 14.12.1. Oncology 14.12.2. Blood 14.12.3. Central Nervous Systems 14.12.4. Endocrine 14.12.5. Cardiovascular 14.12.6. Respiratory 14.13. Japan Orphan Drug Market Forecast, by Drug Type 14.13.1. Biologics 14.13.2. Non-Biologics 14.14. Japan Orphan Drug Market Forecast, by Sale 14.14.1. Generics 14.14.2. Prescribed 14.15. Japan Orphan Drug Market Forecast, by Therapy Class 14.15.1. Oncology 14.15.2. Blood 14.15.3. Central Nervous Systems 14.15.4. Endocrine 14.15.5. Cardiovascular 14.15.6. Respiratory 14.16. Indonesia Orphan Drug Market Forecast, by Drug Type 14.16.1. Biologics 14.16.2. Non-Biologics 14.17. Indonesia Orphan Drug Market Forecast, by Sale 14.17.1. Generics 14.17.2. Prescribed 14.18. Indonesia Orphan Drug Market Forecast, by Therapy Class 14.18.1. Oncology 14.18.2. Blood 14.18.3. Central Nervous Systems 14.18.4. Endocrine 14.18.5. Cardiovascular 14.18.6. Respiratory 14.19. Malaysia Orphan Drug Market Forecast, by Drug Type 14.19.1. Biologics 14.19.2. Non-Biologics 14.20. Malaysia Orphan Drug Market Forecast, by Sale 14.20.1. Generics 14.20.2. Prescribed 14.21. Malaysia Orphan Drug Market Forecast, by Therapy Class 14.21.1. Oncology 14.21.2. Blood 14.21.3. Central Nervous Systems 14.21.4. Endocrine 14.21.5. Cardiovascular 14.21.6. Respiratory 14.22. Rest of Asia Pacific Orphan Drug Market Forecast, by Drug Type 14.22.1. Biologics 14.22.2. Non-Biologics 14.23. Rest of Asia Pacific Orphan Drug Market Forecast, by Sale 14.23.1. Generics 14.23.2. Prescribed 14.24. Rest of Asia Pacific Orphan Drug Market Forecast, by Therapy Class 14.24.1. Oncology 14.24.2. Blood 14.24.3. Central Nervous Systems 14.24.4. Endocrine 14.24.5. Cardiovascular 14.24.6. Respiratory 14.25. PEST Analysis 14.26. Key Trends 14.27. Key Developments 15. ME & Africa Orphan Drug Market Analysis 15.1. Key Findings 15.2. ME &Africa Orphan Drug Market Overview 15.3. ME &Africa Orphan Drug Market Forecast, by Drug Type 15.3.1. Biologics 15.3.2. Non-Biologics 15.4. ME &Africa Orphan Drug Market Forecast, by Sale 15.4.1. Generics 15.4.2. Prescribed 15.5. ME &Africa Orphan Drug Market Forecast, by Therapy Class 15.5.1. Oncology 15.5.2. Blood 15.5.3. Central Nervous Systems 15.5.4. Endocrine 15.5.5. Cardiovascular 15.5.6. Respiratory 15.6. ME &Africa Orphan Drug Market Forecast, by Country 15.6.1. GCC 15.6.2. South Africa 15.6.3. Rest of MEA & Africa 15.7. GCC Orphan Drug Market Forecast, by Drug Type 15.7.1. Biologics 15.7.2. Non-Biologics 15.8. GCC Orphan Drug Market Forecast, by Sale 15.8.1. Generics 15.8.2. Prescribed 15.9. GCC Orphan Drug Market Forecast, by Therapy Class 15.9.1. Oncology 15.9.2. Blood 15.9.3. Central Nervous Systems 15.9.4. Endocrine 15.9.5. Cardiovascular 15.9.6. Respiratory 15.10. South Africa Orphan Drug Market Forecast, by Drug Type 15.10.1. Biologics 15.10.2. Non-Biologics 15.11. South Africa Orphan Drug Market Forecast, by Sale 15.11.1. Generics 15.11.2. Prescribed 15.12. South Africa Orphan Drug Market Forecast, by Therapy Class 15.12.1. Oncology 15.12.2. Blood 15.12.3. Central Nervous Systems 15.12.4. Endocrine 15.12.5. Cardiovascular 15.12.6. Respiratory 15.13. Rest of ME &Africa Orphan Drug Market Forecast, by Drug Type 15.13.1. Biologics 15.13.2. Non-Biologics 15.14. Rest of ME &Africa Orphan Drug Market Forecast, by Sale 15.14.1. Generics 15.14.2. Prescribed 15.15. Rest of ME &Africa Orphan Drug Market Forecast, by Therapy Class 15.15.1. Oncology 15.15.2. Blood 15.15.3. Central Nervous Systems 15.15.4. Endocrine 15.15.5. Cardiovascular 15.15.6. Respiratory 15.16. PEST Analysis 15.17. Key Trends 15.18. Key Developments 16. Latin America Orphan Drug Market Analysis 16.1. Key Findings 16.2. Latin America Orphan Drug Market Overview 16.3. Latin America Orphan Drug Market Forecast, by Drug Type 16.3.1. Biologics 16.3.2. Non-Biologics 16.4. Latin America Orphan Drug Market Forecast, by Sale 16.4.1. Generics 16.4.2. Prescribed 16.5. Latin America Orphan Drug Market Forecast, by Therapy Class 16.5.1. Oncology 16.5.2. Blood 16.5.3. Central Nervous Systems 16.5.4. Endocrine 16.5.5. Cardiovascular 16.5.6. Respiratory 16.6. Latin America Orphan Drug Market Forecast, by Country 16.6.1. Mexico 16.6.2. Brazil 16.6.3. Rest of Latin America 16.7. Mexico Orphan Drug Market Forecast, by Drug Type 16.7.1. Biologics 16.7.2. Non-Biologics 16.8. Mexico Orphan Drug Market Forecast, by Sale 16.8.1. Generics 16.8.2. Prescribed 16.9. Mexico Orphan Drug Market Forecast, by Therapy Class 16.9.1. Oncology 16.9.2. Blood 16.9.3. Central Nervous Systems 16.9.4. Endocrine 16.9.5. Cardiovascular 16.9.6. Respiratory 16.10. Brazil Orphan Drug Market Forecast, by Drug Type 16.10.1. Biologics 16.10.2. Non-Biologics 16.11. Brazil Orphan Drug Market Forecast, by Sale 16.11.1. Generics 16.11.2. Prescribed 16.12. Brazil Orphan Drug Market Forecast, by Therapy Class 16.12.1. Oncology 16.12.2. Blood 16.12.3. Central Nervous Systems 16.12.4. Endocrine 16.12.5. Cardiovascular 16.12.6. Respiratory 16.13. Rest of Latin America Orphan Drug Market Forecast, by Drug Type 16.13.1. Biologics 16.13.2. Non-Biologics 16.14. Rest of Latin America Orphan Drug Market Forecast, by Sale 16.14.1. Generics 16.14.2. Prescribed 16.15. Rest of Latin America Orphan Drug Market Forecast, by Therapy Class 16.15.1. Oncology 16.15.2. Blood 16.15.3. Central Nervous Systems 16.15.4. Endocrine 16.15.5. Cardiovascular 16.15.6. Respiratory 16.16. PEST Analysis 16.17. Key Trends 16.18. Key Developments 17. Company Profiles 17.1. Market Share Analysis, by Company 17.2. Market Share Analysis, by Region 17.3. Market Share Analysis, by Country 17.4. Competition Matrix 17.4.1. Competitive Benchmarking of key players by price, presence, market share, Raw material, and R&D investment 17.4.2. New Raw material Launches and Raw material Enhancements 17.4.2.1. Market Consolidation 17.4.2.2. M&A by Regions, Investment and Raw material 17.4.2.3. M&A Key Players, Forward Integration and Backward Integration 17.5. Company Profiles: Key Players 17.5.1. AOP Orphan 17.5.2. Agenus 17.5.3. Alexion 17.5.4. Bristol Myers Squibb 17.5.5. Biogen Idec 17.5.6. Celgene 17.5.7. Eli Lilly 17.5.8. Genethon 17.5.9. Genzyme Corporation 17.5.10. Glaxosmithkline 17.5.11. Merck 17.5.12. Novartis Pharmaceuticals 17.5.13. Orphan Europe 17.5.14. Pfizer 17.5.15. Prosensa 17.5.16. Rare Disease Therapeutics 17.5.17. Roche 17.5.18. Sanofi 17.5.19. Shire 17.5.20. Teva Pharmaceutical. 18. Primary Key Insights

About This Report

Report ID 73739
Category Healthcare
Published Date Oct 2020
Updated Date
Contact Us